Raymond James Financial Inc. purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 915,361 shares of the biopharmaceutical company's stock, valued at approximately $76,451,000. Raymond James Financial Inc. owned 0.86% of Intra-Cellular Therapies as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of ITCI. TimesSquare Capital Management LLC increased its position in shares of Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company's stock worth $70,179,000 after buying an additional 402,186 shares during the period. Eagle Asset Management Inc. grew its holdings in Intra-Cellular Therapies by 130.5% during the 3rd quarter. Eagle Asset Management Inc. now owns 624,759 shares of the biopharmaceutical company's stock worth $45,714,000 after acquiring an additional 353,723 shares during the period. Franklin Resources Inc. raised its position in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock worth $129,463,000 after acquiring an additional 155,655 shares in the last quarter. Wasatch Advisors LP lifted its stake in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock valued at $281,601,000 after purchasing an additional 130,351 shares during the period. Finally, Westfield Capital Management Co. LP boosted its position in shares of Intra-Cellular Therapies by 11.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,159,356 shares of the biopharmaceutical company's stock valued at $84,830,000 after purchasing an additional 116,494 shares in the last quarter. Institutional investors own 92.33% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their target price for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their price target for the company from $140.00 to $132.00 in a research note on Monday, February 24th. StockNews.com began coverage on Intra-Cellular Therapies in a research note on Wednesday. They issued a "hold" rating for the company. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Ten research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has an average rating of "Hold" and an average target price of $106.08.
Read Our Latest Stock Analysis on Intra-Cellular Therapies
Intra-Cellular Therapies Stock Performance
ITCI stock traded up $0.11 during mid-day trading on Thursday, hitting $131.36. The company had a trading volume of 1,909,588 shares, compared to its average volume of 1,320,320. The stock's fifty day moving average price is $122.06 and its two-hundred day moving average price is $94.74. Intra-Cellular Therapies, Inc. has a 12 month low of $63.30 and a 12 month high of $131.37. The firm has a market cap of $13.97 billion, a PE ratio of -150.99 and a beta of 0.69.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.
Intra-Cellular Therapies Company Profile
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Stories
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
